TOD™ Project Business Plan

Company Private – May 20, 2022

"The Age of Tissue Computing has Arrived™"

Brought to you by BCM Industries

Executive Summary

BCM Industries Inc. ("BCM") has, over the last two years, emerged as a significant industry global leader in tissue engineering and regenerative medicine. This was the result of the creation and delivery of advanced Autologous Regenerative Tissue Replacement (ARTR™) organ repair products, processes, and technologies. Exploiting these capabilities is still a key aspect of BCM's business but the critical need and high demand for neuron processing caused BCM to direct skills, assets, and energy to address an area of tissue engineering, known as neuron or neural processing.

The result is "The Age of Tissue Computing has Arrived™." BCM has designed and this year will begin commercial sales and delivery of Desktop Tissue Computers. This family of nine Tissue Operating Device (TOD™) Models will deliver living tissue containing from 16 million to 5 billion active neurons. The result is blinding throughput and processing speeds, and near-limitless data storage capacities.

To facilitate these expanded product lines, BCM is acquiring funds through the sale of BCM common stock. For details contact a BCM representative. The pro forma financial performance of BCM is presented in Figure 1, BCM Pro Forma Earnings. The BCM share valuation, pricing, and ROI are illustrated in Figure 2, Investor Pro Forma ROI.

>>>>><<<<<

Table of Contents

1. Introduction

BCM Industries Inc. (“BCM”) has over the last two years emerged as a significant industry leader in tissue engineering and regenerative medicine, with specific emphasis on the creation and delivery of advanced Autologous Regenerative Tissue Replacement (ARTR™) organ repair products, processes, and technologies.

These BCM-developed tissue technologies, skills, assets, and processes are not restricted to the repair of human organs. There are many new and expanding applications for live tissue creation and operations.

One of the most commercially viable applications is Tissue Computing. As illustrated in Figure 3, automated computing commenced with the vacuum tube, moved to silicon chips and the next leap forward is to Tissue Computing. Tissue Computing is the future of processing and will impact everyone and nearly everything.

It is well known that the human brain can massively outperform digital silicon chip computers when addressing certain processing applications. Given this fact, many computer companies, universities, and others have been diligently pursuing means to emulate the performance of the human brain in some form of a modified digital chip. For a detailed discussion of their efforts, review the Article: “Introduction to TOD™ and Tissue Computing,” and other related Articles available from BCM.

Based upon the continually growing market demand for user access to neuron processing services, IBM, Intel, Graphcore, BrainChip, and others are offering special chip performance enhancements for selective parallel processing applications.

They are having some success. However, all digital chip processors and memory devices are performance limited by the physical constraints of the chip and motherboard architecture. Conventional digital computers with chips and motherboards, no matter how enhanced, will never achieve the levels of performance of a pure Tissue Computer.

Knowing this limitation on chips and motherboard, BCM initiated Project TOD™ to design, manufacture, and commercialize a Tissue Computer with significant neuron processing capabilities. The success of Project TOD™ was assured before starting because BCM had already acquired or created all the individual components and elements needed to produce a family of commercial Tissue Computers.

The BCM team brings to Project TOD™ decades of experience and skills in all forms of tissue engineering, cell growth, tissue population management, and related tissue computing engineering and technologies. These include the recent design of a highly automated, low-cost mass production tissue manufacturing facility.

This BCM Business Plan addresses the tasks, processes, resources, and activities required to complete Project TOD™. Successful in this context means continual expansion of volume manufacturing, sales, and delivery of a family of commercially desirable TOD™ Models to global customers.

2. Tissue Computing

Tissue computing is the future of processing, and both neuron and quantum processing are rapidly advancing revolutionary approaches to high-speed processing and storage of information. Big companies, universities, governments, and big money are joining these advancements. Figure 4 summarizes the processing speed and scheduled availably of TOD™ Models offering neuron, and potentially quantum, processing services.

Neuron Processing - Before TOD™, neuron processing was defined as using specialized computer chips and motherboards to artificially emulate the actions of neurons or nerve cells. Intel, IBM, and others currently have available computer hardware and software that can artificially emulate millions of neurons in a processing capacity.

In an alternative approach, BCM uses live neurons resident in a Tissue Computer to deliver neuron processing. With no computer chips and no motherboard, TOD™ is redefining neuron processing by delivering live neurons in a massive and expandable learning capacity, delivering extremely complex data processing capabilities.

Conventional or Classical digital computers with chips and motherboards, no matter how enhanced, will never achieve the levels of neuron processing performance of a live neuron arrayed Tissue Computer. See the Articles provided under the TOD tab on the BCM Industries website.

Quantum Processing - Before TOD™, quantum processing was defined as using computer chips and motherboards operating at near absolute zero temperatures to perform or emulate the activities of quantum physics. The TOD™ approach to quantum processing is to use live neurons as the processing embodiment to perform quantum computing at body temperature. If current theoretical science is correct, TOD™ based quantum processing may occur within a Tissue Computer containing millions of live neurons.

3. TOD™ Configuration

As illustrated in Figure 5, a TOD™ system includes three major components: a Tissue Computer, a Management Computer, and a TOD™ configured laptop computer. For details regarding these components and specifics on the Tissue Computer (TC) processing features, and array architecture, see the Articles provided under the TOD tab on the BCM Industries website.

TOD™ Models will be commercially offered to address both general and special purpose neuron processing. As presented in Figure 6, the TOD™ family of processors is offered in nine unique Models offering from 16 million to 5 billion neuron-powered processing and data storage options.

The TOD™ Model 16 is the smallest, delivering a maximum of 16 million neurons from a standard-sized desktop or floor tower. The next size, the TOD™ Model 48, delivers up to 48 million neurons in a larger floor version or a rack-mounted configuration.

The largest TOD™ Model offered, the 5120, can provide a maximum of five (5) billion neurons, Although potentially possible, BCM has not addressed the networking of multiple TOD™ Model 5120 units to obtain larger programable pools of available neurons. Initially, all available TOD™ Models are configured for fixed operations. However, BCM is developing mobile-ruggedized versions of some models.

Of the three TOD™ components, the Tissue Computer represents the development challenge. It had to be an extremely reliable neuron processor constructed of continually nurtured tissue disks (TC Disk), able to be massively populated with neurons. The tissue structures were required to be assembled into processing arrays. The design had to address modularity, an expandable neuron processor architecture, and all internal data transfers had to be over tissue cords (TC Cord), also heavily populated with neurons.

Another challenge is the design, manufacture, and delivery of a safe and dependable medically sterile closed operating environment for the tissue processing array and millions of neurons with a useful life of up to forty years. These tasks, including high volume, live tissue manufacturing, BCM has previously perfected with the tissue engineering required to design, manufacture, and deliver ARTR™ organ repair tissue implants.

4. Digital Computers

Each TOD™ includes two separate and independent digital computers. They function as the controller and manager of the Tissue Computer, and also the user interface with all TOD™ activities.

TOD™ Configured Laptop - is a conventional digital laptop computer that has been configured with an operating system, utilities, tools, and application programs that provide users access to and the ability to program and control the services offered by the TOD™. This laptop can be networked to all types of private and public data networks to access, transfer, and process data.

TOD™ Management Computer – is a conventional digital processor that has been specifically configured to operate the Tissue Computer and to monitor and control all digital data that flows into and out of the Tissue Computer. In addition to user application interfaces, this Management Computer is responsible for the safe and full environmental control and operations of the Tissue Computer. It uses the TOD™ Configured Laptop and other digital ports as the I/O devise to communicate with the TOD™ system administrator and the many users.

5. The Tissue Computer

Each TOD™ includes one Tissue Computer. This computer is the neuron processor of the TOD™ system configuration. It contains living tissue highly populated with up to 16 million to 5 billion neurons, depending upon the Model. To assure continuous and robust processing this Tissue Computer must hold, continue to support, and provide a living tissue environment for all the resident neurons.

To remain effective in addressing processing applications, these many millions of neurons must be structured and configured in an ordered and programmable computer architecture. Also, they must be able to be accessed and controlled by the system administrator, operating systems, and users with access to the Management Computer and/or the TOD™ Configured Laptop computer.

To avoid neuron-caused operational processing chaos, the Tissue Computer includes two specialized tissue structures. One is the TC Disk, and the other is the TC Cord.

TC Disk – is a disk-shaped cluster of tissue that is physically about 2x2x0.5 includes, or about 2 cubic inches of live tissue. It is not rigid but a soft-shaped disk. Each TC Disk is populated with up to one million active neurons that are addressable and programmable as an item or element of the Tissue Computer.

Figure 7 is an actual picture of a fully populated TC Disk in a Petrie dish. This TC Disk is embedded with approximately one million neurons and is ready for insertion into a Tissue Computer Array.

TC Cord – is a cord-shaped flexible tissue structure. When filled with tissue and fully populated with neurons a TC Cord functions similar to a nerve or spinal cord structure. The diameter varies per application and can be less than 20 micrometers up to 8 millimeters. The cord length varies depending upon the application. The function of the TC Cord, within the Tissue Computer, is to utilize neurons, within the TC Cord, to move data at high speeds and great bandwidths between TC Disks or through a Tissue Computer port.

Figure 8 illustrates a TC Cord section with the interior of the Cord filled with Tissue that is heavily populated with neurons. This Figure also illustrates a different type of TC Cord. It is a branching section that can support the building of TC Cord networks needed to link together many TC Disks within an Array.

6. Tissue Computer Architecture

For TOD™ Models to obtain the desired neuron processing performance from all the many millions of neurons resident in the Tissue Computer, all the TC Disks and TC Cords must be structured and organized to function as a reliable and effective processing unit. To accomplish this mission, the Tissue Computer has been organized into an Array structure.

Figure 9 illustrates a basic 4-set TC Disk and TC Cord linkage network. This form of networking is the bases of all Tissue Computer architectural Arrays. Each TC Disk is connected to at least two TC Cords. These TC Cords are prevalent throughout the Array. One end of each TC Cord is tissue embedded into a TC Disk. These TC Disk embedded data ports are identifiable and programmable by the Management Computer software and the TOD™ Configured Laptop operating system and application programs.

The TOD™ Tissue Computer processing architecture uses two unique array structures. One is a Planar Array and the other a Cubic Array.

Planar Array – is an arrangement of TC Disks in a flat 2-dimensional pattern. It includes 4 TC Disks across and is 4 TC Disks high. Illustrated in Figure 10 this Array is a 16 TC Disk Planner Array. Currently, this Array is only used in the TOD™ Model 16. It delivers up to 16 million neurons for processing and is small enough to allow the Tissue Computer to reside inside of a standard desktop or floor tower. (See Figure 11).

Cubic Array - is an arrangement of TC Disks in a cubic 3-dimensional pattern. It includes three, 3D stacked, 16 TC Disk Planner Arrays. Linked by TC Cords in all three directions. This Array delivers 48 TC Disks across a 3D cube. Illustrated in Figure 12, this Array is a 48 TC Disk Cubic Array. Currently, this Array is used in the TOD™ Model 48. It delivers up to 48 million neurons for processing and fits comfortably into the Tissue Computer that resides in a floor version with a total volume equal to four standard towers. This Model is also available in a rack version.

Larger Tissue Computer Configurations

The 48 TC Disk Cubic Array is the baseline design architecture for all Tissue Computers that support the larger numbered TOD™ Models, beginning with Model 96 and extending through Model 5120. Figure 13 illustrates how the 48 TC Disk Cubic Array is configured to build a Model 96 and a Model 192.

Figure 14 illustrates how a Model 96 can be reconfigured by the Management Computer and/or the TOD™ Configured Laptop to operate as two separate Model 48 units. They can be set up to independently perform processing tasks or parallel process the same tasks, where one acts as a full real-time back processor.

Networking and Direct Sensor Sourced Data

Low to moderate bandwidth networking of multiple numbers of the same TOD™ Models and/or a mixture of TOD™ Models is possible using currently available commercial digital network services.

All Tissue Computer internal data networking is neuron-to-neuron, using the TC Cord network. BCM is also developing a special flexible pipeline protected TC Cord, which may support direct neuron-to-neuron data transfers between multiple TOD™ systems and rack-mounted Tissue Computers.

In addition to neuron and digital data transfers, BCM is developing TC Cords and interface ports for the Tissue Computer to support raw, direct sourced data in these formats: optical, audio, video, RF, Inferred, thermal, and seismic.

7. Manufacturing and Delivery

Manufacturing a TOD™ computer with live tissue, populated with millions of neurons is complex and challenging. However, BCM has previously, and repeatedly performed all these manufacturing steps and maliciously validated all the processes, equipment, and procedures. The latest tissue production system validation was in the manufacturing and delivery of multiple sets of Autologous Regenerative Tissue Replacement (ARTR™) organ repair tissue units in support of human kidney repair clinical trials. To learn more, review the ARTR™ data at the BCM website. For additional information on TOD™ manufacturing see the Article: “Manufacturing, Packaging, and Transport,” and other Articles available from BCM.

The Tissue Computer is filled with neuron populated tissue structures. Because this Computer contains many millions of living neurons, the manufacturing processes must be performed within a medically sterile, Lab type, manufacturing environment.

In the tissue manufacturing process, BCM utilized only bovine sourced materials that meet or exceed all U.S. FDA recommended “Guidelines as to Pedigree and Handling” procedures for materials to be used in medical devices. BCM’s controlled sourcing process assures a pure material that contains no growth-stimulating hormones or GMO products used in the birthing and raising of the bovine herds.

All BCM processing and manufacturing are performed under strict Standard Operating Procedures and are cGMP (“current good manufacturing practice”) compliant, and compliant with the USDA and FDA regulations. These operating controls, procedures, and qualified processes enable BCM to provide the highest quality and purity of materials used in the manufacture of each Tissue Computer.

Installation, Operations, and Maintenance

All TOD™ Models are sold under a one-year full replacement warranty. That warranty includes customer on-site delivery and complete professional installation by a TOD™ Support Team. The on-site team assembles, connects, evaluates, and performs full system tests to assure each delivered TOD™ Model fully meets or exceeds all performance standards.

Utilities, Tools, and Application Programming

Two of the TOD™ system components are digital computers: the Management Computer and a TOD™ configured laptop computer. There are many general-purpose and specialized digital programming utilities, tools, and application programs available to address these digital segments of the TOD™ system configuration.

Because TOD™ includes the first commercially available Tissue Computer and offers users direct programming access to millions of neurons, neuron-specific software utilities, tools, and application programs to operate, manage, and leverage the neuron performance capabilities are required.

For more than a decade a growing community of scientists, engineers, and application developers interested in neuron processing has been building and using software that is focused on neural networks and neuron processing. The result is that many of the software utilities, tools, and application programs required to manage and control the TOD™ Tissue Computer are currently available, and many are open-source. These programs are either directly TOD™ compatible, or with modification can become a part of the TOD™ and Tissue Computer software users' library.

System Security and Viruses

TOD™ is vulnerable to three classes of threats and is designed and operated to fully defend the system against all three. The first two classes are common to all digital computers. They include physical security and digital data hacking and virus attacks. The TOD™ security system addresses these two classes of threats in a manner currently utilized to secure large digital processing systems and high-security databases.

Because TOD™ includes a Tissue Computer that operates using live tissue highly populated with millions of neurons, BCM has developed a special new class of system defenses against live-cell threats. These special defenses address bacterial infections, cell attacking viruses, and other destructive cell and tissue threats. To protect the Tissue Computer and the embedded live cells, BCM has developed proprietary cell defensive security software and other advanced cell protection technologies.

8. Business Management and Operations

BCM has an established and experienced management team and a staff of highly skilled design, development, and manufacturing engineers and scientist in the fields of tissue growth and management, live tissue neuron processing, and digital hardware, software, and networks. The TOD™ Project presents challenges but they are ones the BCM team has previously addressed and holds applied knowledge and skills to address.

Intellectual Property Assets

The Company owns and continues to acquire and create Intellectual Property (IP) assets. These IP assets address many technologies, procedures, processes, and operations being utilized by BCM in tissues based and other products and applications.

New IP assets are continually being added. They include many operating processes, procedures, rules, and technologies that assure successful management and daily operations of the Tissue Computer hardware and software.

They also address tissue manufacturing and TOD™ delivery, installation, and operational technologies and processes; plus, the design and operation of specialized programming utilities, tools, and software to manage and control the TOD™ equipment and operating systems.

In recent years, the asset protection effectiveness of US and Foreign patent laws, administrative procedures, and the courts have been far from effective in protecting the owner's IP assets. Therefore, to assure full global protection of IP assets, the Company has implemented, both general and specific, Trade Secrets and Proprietary Property programs. These corporate enforced programs control and limit assess, manage, assure accountability, and deliver global protection of all of the Company's IP assets.

Copyright and Trade Secret Protection

The Company's intellectual property (IP) rights are granted legal protection under the Trade Secret, Trademark, Service Mark, and Copyright laws of the United States and other foreign countries. These laws provide substantial civil and criminal sanctions for unauthorized theft, duplication, and exhibition.

The Company plans to secure and maintain protection for its intellectual and other property rights to all of its properties under the laws of applicable jurisdictions. In addition, the Company intends to utilize the traditional safeguards employed in the industry to protect its creative properties and assets. The Company does not hold any patients and uses proprietary properties and trade secret programs and procedures for the protection of IP assets.

Competition

Competition in the Tissue Computing industry is growing and likely to become highly intense over the next decade. In addition, advances in both chip and tissue computing will continue.

BCM views this forthcoming competition as a positive challenge that will drive innovation and creativity. BCM believes its assets, team, highly automated tissue manufacturing capabilities, and business model will assure the Company maintains a leadership position and continues to create positive advances in technology and products, and earnings growth for the near future.

Facilities

The Company presently operates research and production facilities in New Jersey and intends to arrange for additional facilities in Texas, and potentially other multinational locations. The Company utilizes many independent contractors who operate from locations remote from the administrative office and production locations. The Company believes its headquarters and other facilities will be adequate to support the Company's facility needs for the near term.

Property and Technology Licensing

The Company licenses operating rights, technologies, processes, procedures, patent rights, computer code, and other intellectual property rights from various sources. All of the owned and licensed intellectual property is paid current and no foreseen interruption to the access of these licensed properties are anticipated.

TOD Models will require new proprietary software, and technology licenses, in the areas of neuron-digital interfaces, neuron and quantum processing software, and others. In each of these areas, the Company anticipates favorable licensing terms will be available.

Funding Rounds and Use of Funds

As illustrated in Table 1, the Company plans to offer three funding rounds. Each round addresses another phase of expansion and growth of the TOD™ Project. The third round will be funded either by an initial public offering of BCM shares, a reverse merger, or another type of public funding procedure. Rounds one and two are scheduled to be completed with the private placement of BCM shares.

Employees and Contractors

Over the next three years, the Company will expand both U.S. and global operations. The Company has been successful in its efforts to recruit qualified employees and contractors. The Company anticipates sufficient qualified employees and/or independent contractors will be available to fulfill future staffing needs. None of the Company's present employees are subject to collective bargaining agreements.

Management and Staffing

The Company has assembled an outstanding team of highly skilled, innovative, persistent, and professional individuals. This team has succeeded in acquiring and creating a stellar core of assets and technologies, which has positioned BCM to become a global leader in advanced tissue engineering and manufacturing.

To address the growth needed to deliver TOD™, the Company has identified sources of highly skilled and professionally qualified individuals in all required staffing areas. These areas include but are not limited to BCI hardware and software, neuron, and quantum technologies and software, tissue engineering and manufacturing, business management, finance, marketing, sales, and other skills.

The senior management and development team includes a combination of employees, advisors, and consultants. Additional management team, professionals, and other staffing will be added as required to support growth. Highlights of a few staff members follow.

Glenn Gearhart, JD, MSE, BSEE, is the Founder, CEO, and Chairman of BCM Industries Inc. Dr. Gearhart has over 45 years of professional experience in business development, operations, management, law, and computer sciences and engineering. He has repeatedly demonstrated the ability to assemble a quality team, provide leadership and motivation, accept, and respond to challenges, and record significant personal and corporate achievements in business and the high-tech computer industries.

His legal experience includes securities law, corporate finance, international business and corporation development, general corporate law, real property law, and civil litigation. Dr. Gearhart is a member of the California State Bar, holds a JD in Law from Western State University, an MS in Systems Engineering from West Coast University, and a BS in Electrical Engineering from Trine University.

J. Roy Nelson, Ph.D., Senior Vice President, Chief Scientific Officer (CSO), Tissue Engineering, and Director of Quality, and the Collagen Structure Regenerative Cell Testing Laboratory. Dr. Nelson is a specialist in applied surface quantum mechanics and polymer science. In addition to BCM responsibilities, Dr. Nelson manages a medical manufacturing facility and material testing laboratory that specializes in particle and surface science for the pharmaceutical industry. The laboratory has a US-DEA Schedule IV Drug License and is FDA audited.

Dr. Nelson received his B.S. degree in drug chemistry from UCLA, his M.S. in synthetic organic (drug) chemistry from the University of Illinois, and a Ph.D. in material/polymer science from Penn. State University. He has over 35 years of experience and holds 25 U.S. and Worldwide Patents.

Cliff Dey, Ph.D. ME, MSME, BSME, Senior Vice President, Chief Manufacturing Engineer (CME). He is responsible for the design, development, and installation of all tissue manufacturing and processing systems and equipment. Dr. Dey has over 40 years of experience, holds many patents, and received the Thomas Edison Patent Award for Medical Devices in 2020.

David R. Richards, Ph.D., Senior Vice President, Business and Market Development. He is reasonable for assisting the Company in both US and global expansion and sales. Dr. Richards is a highly acclaimed author, speaker, and facilitator of strategic innovation leadership. He is a co-founder of the MIT Innovation Lab, a globally experienced senior executive, and has served various enterprises as a board director or advisor. He holds a Ph.D. in Mathematical Psychology and Neuroscience from the University of Toronto.

Kevin Gearhart, Chief Operations Officer (COO). Mr. Gearhart has over twenty-five years of experience in managing financial operations, sales, business operations, customer service, inventory, and supply chain systems, and corporate asset management. Mr. Gearhart has repeatedly demonstrated his ability to manage and operate growth-oriented business entities.

His experience includes participating in the creation, design, operation, and development of BCM Industries, plus operations management and sales management of both retail and online vendors and service providers.

Radka Milanova, PhD, Senior Vice President. Dr. Milanova is a highly-skilled professional with academic credentials and qualifications merging business management, marketing, and regulatory strengths, licensing, and collaborations in the pharmaceutical, nutraceutical, and veterinary industries. Dr. Milanova served for several years as a Board Director on companies, such as the multinational generic pharmaceutical company Biovet Peshtera, Bulgaria, LinkCore Pharma Limited, UK as well as POS Biosciences in Saskatoon, Canada. Dr. Milanova earned her award-winning doctorate from Simon Fraser University (SFU), Canada.

Martial Frigon, Vice President, Developing Markets. Mr. Frigon is a versatile entrepreneur with over 25 years of experience in law, finance, business development, marketing, sales, management, and communication. He has continually recorded successes in international marketing and sales. Mr. Frigon resides in Canada and is bilingual in French and English.

Ethan Stanley, Vice President, Processing Systems and Services. Mr. Stanley provides established experience and skill in both management and participation in the creation, design, operation, and development of multiple numbers of advanced processing and tissue engineering technologies and systems.

Linda Hoy, Vice President, Finance and Human Resources. Ms. Hoy has demonstrated superior abilities to operate a business and address fiscal management of multi-regional organizations and has the skills required to unite many individuals, with differing opinions and skills, to focus and join together to accomplish difficult missions.

Kathy Paquette, Vice President, Graphics and Media Services. Ms. Paquette has over twenty-five years of direct experience in domestic and international promotions, media, marketing, and sales operations. She has superb skills in promotion, computer graphics, art, creative graphics, marketing presentation development, and related marketing and sales skills.

Shauna Guerin, Senior Vice President, Global Product Distribution and Markets. Ms. Guerin has over thirty years of experience in managing financial operations, business operations, customer service, administration, and corporate asset management. Her management and operating experience span computer and system operations, inventory management and automation, software development, production systems development, music recording, distribution and publishing, human resource management, and production staff training.

Dennis McDonough, Vice President, Digital and Network Services. Mr. McDonough is responsible for the design and operation of software applications, data networks, and IT aspects of the products and services utilized by BCM operations.

He has over 40 years of experience in computer software development, graphics, payment systems, IT technology, smart contracts, network operations, data storage, Internet operations, data communications, IT system security, website development, Internet service provider operations, cloud processing, secure data center operations, and application software design, development, and testing. He holds a bachelor's degree from Indiana State University.

9. Markets

There is growing global demand by corporations, universities, governments, militaries, and even individuals, for both neuron and quantum processing systems and services.

This market demand is validated by the significant resources being committed to these technologies and systems by IBM, Intel, Google, Honeywell, Xanadu, IonQ, Rigetti, Alibaba, Amazon, Qualcomm, Graphcore, BrainChip, and others.

As presented in Table 2, Potential TOD™ Market Size By Market Categories, which excludes potential government, military, and individual consumer markets. Addressing only the business and university the data indicates the total potential market that exceeds 744 million customers.

Compare this potential 744 million customer base, with a total number of 182,828 TOD™ systems scheduled to be sold in the first few years. With this comparison, it appears BCM will locate adequate customers to complete the sales forecasts through 2024.

Another approach to the market is addressed in Table 3, TOD™ Sales Compared to Computer Industry. Again, in reviewing this customer base, BCM should fulfill the scheduled sales of 182,828 TOD™ systems through 2024.

Marketing Phycology and Processing Speeds

The modern business and individual consumer markets have been conditioned to live in two states of mind, known as the phycology of human desire and frustration. These mind states are commonly represented in two responses: I must have it now (*immediate gratification*); and the other is: Do not tell me I cannot have it (*gratification denial*).

Whether needed or not, this embedded phycology of human desire and frustration is the driving force behind the sales of fast cars, fast foods, fast computers, fast video games, and much more. Therefore, whether the product is needed or not, as illustrated in Figure 4, fast processing speeds, high throughputs, and massive data storage capacities offered by TOD™ Models fit the two states of mind marketing phycology.

Neuron Processing - TOD™ Models, as tissue data processors, for many tasks, are 1,000 times faster than classic digital computers. A large processing task that would require 1,000 seconds, (16.7 minutes) on a classic digital computer is completed in one (1) second using TOD™ in a neuron processing mode. That is amazing speed, which will sell TOD™ systems.

In summary - a neuron performance comparison: TOD™ one second and a classic computer 16.7 minutes.

The ultimate cost to benefits analysis of a TOD™ Model purchase depends upon the specifics of the data processing applications to be addressed, and the reductions in manpower, electrical power, thermal heat dissipation, floor space, and other organization operational savings.

For a brief introduction to a few of the many thousands of big data research, business, space, finance, and military applications to which TOD™ can deliver major benefits, see the related Articles available from the BCM website on the TOD tab.

10. Financial Performance

This Business Plan is based upon the initial release and delivery of a limited number of TOD™ Model 16 units during the 4th quarter of 2022. Increased production of TOD™ Models will occur during 2023-2024 with quantiles and Model numbers consistent with customer purchase orders and payments.

In 2022, BCM will address the finalization of the TOD™ Models, with the delivery of up to ten Model 16 units during the last quarter of the year. In the same year, BCM will also address the setup and commence highly automated TOD™ manufacturing of TOD™ Models. These activities will establish the complete processes and systems required to support increased production and delivery of the TOD™ system in 2023, 2024, and beyond.

To obtain the funds required to complete these tasks, the Company is selling shares, in two private funding rounds, and later in a public share sales event, an IPO. The funding round amounts, and use of funds. and other data are presented in Table 1, BCM Funding Rounds and Use of Funds.

The process of forecasting BCM earnings and investor potential Return On Investment (ROI) for BCM shareholders requires the establishment of TOD™ Model production and sales rates, operating expense projections, and other data. As supporting background, and foundational data to the establishment of the ROI data, four Tables are provided.

Table 4, Commercially Available TOD™ Models and Pricing, provides the scheduled pricing for each of the nine Models. Many buyers will prefer to make incremental purchase payments as their TOD™ system is being manufactured. Table 5 presents available incremental payment options.

Table 6 presents the schedule of TOD™ Models to be manufactured and delivered in the years 2022, 2023, and 2024. A total of 182,828 TOD™ systems are scheduled to be delivered during these three years. The scheduled number of TOD systems sold, and the forecast annual revenues are presented in Table 7, Pro Forma Annual BCM Revenues, for five years of operations.

Based on data in the prior Tables, the ROI data is presented in Table 8, Pro Forma BCM Five-Year Earnings and Valuation. This data is also illustrated in Figure 1, BCM Pro Forma Earnings, and Figure 2, Investor Pro Forma ROI. The share prices assume no share stock splits occur during the period.

Figures and Tables

>>><<<

Figure 1

BCM Pro Forma Earnings



Source: BCM Business Plan, TOD™ Project, February 2022, See Offering for Specifics

Figure 2 14

Investor Pro Forma ROI



Figure 3

Live Tissue Processing Speed and Availability

Type	Speed Increase (*)	Availability
Neuron Processing	1,000 Times	Late 2022 9 Models
Quantum Processing	One Million Times	Developing Mid 2023 (Est.)

(*) Over classic silicon chip computers addressing selective applications

Figure 4



Figure 5

TOD™ System Configuration



Figure 6

TOD™ Models

A family of Nine Commercially Available Tissue Computers (*)

Model 16	Model 48
Model 64	Model 96
Model 192	Model 480
Model 1024	Model 2048

Model 5120 – offers over 5 billion neurons

(*) Model Number Defines Number of Available Neurons

Figure 7

Single TC Disk Embedded with Neurons

Single TC Disk in a Petrie Dish
TC Disk Embedded with up to
One Million Neurons
Ready for Insertion into Tissue
Computer Array

Figure 8

Standard and Networked TC Cords

Standard TC Cord
TC Cord Section filled with Tissue
Tissue Embedded with Neurons

Network Branching TC Cord
Network Branching TC Cord Section
Internal Tissue Structure and
Embedded Neurons Absent

Figure 9

4 TC Disk – TC Cord Linked Tissue Array



Segment of a neuron processing array

Code:
○ TC Disk
■ A TC Cord
— A TC Disk Embedded Data Port
Note: All TC disks are identifiable and programable tissue computer components addressable by the management computer operation system

Figure 10

16 TC Disk Programable Planar Array

Tissue Computer



2D Planar Tissue Processing Array

Code:
● A single TC Disc
— A single TC Cord
Note: All TC disks are connected to at least 2 or more TC Cords

Figure 11



Figure 12



Figure 13

48 TC Disk Cubic Array Architecture
TOD™ Model 96 and 192 Configurations



Code:

48 A standard 48 TC disk cubic array

Note: Illustration shows difference between Model 96 and Model 192

Figure 14

Model 96 in Full Real-Time Backup



TOD™ Model 96 program partitioned into a model 48 with full-time duplicate processing.

Code:

48 A standard 48 TC disk cubic array

Table 1

BCM Funding Rounds and Use of Funds

Funding Round	Maximum $ Amount Raised	Funding Source
One [1]	$10 Million	Private
Two [2]	$100 Million	Private
Three [3]	$500 Million	Public

Notes
[1] Funding is used to complete TOD™ system development and integration, establish an initial TOD™ manufacturing facility, and deliver and install up to 10 Model 16 TOD™ systems.
[2] Funding was used to complete TOD™ system development and integration and expansion of US manufacturing facilities and to support expanded delivery and installation of TOD™ Models 16, 48, 64, and 96.
[3] Funding was used to expand the US and to establish additional TOD™ manufacturing facilities, and sales/support centers, in India, South America, the EU, and Asia.

Table 2

Potential TOD™ Market Size By Market Categories

Purchaser Category	USA Number	India Number	Asia Number	EU Number	Totals Number
Colleges and Universities (Thousands)	6 [1]	51 [2]	5.9 [3]	2.7 [4]	65.6
Large Sized Businesses (Thousands)	21 [5]	35 [6]	395 [7]	263 [8]	714
SME [9] Businesses (Millions)	30 [10]	63 [11]	628 [12]	22.6 [13]	743.6
Total (Potential Customers- Millions)					**744.4**

Potential Customers Compared to Pro Forma TOD™ System Sales

Total TOD™ Models Sold	Year 2022	Year 2023	Year 2024
Models [14]	10	15,018	167,800
Total (TOD™ Systems Sold)			**182,828**

Notes:
[1] USA Colleges and Universities - https://www.bestcolleges.com/blog/how-many-colleges-in-us/
[2] India Colleges and Universities - https://www.statista.com/statistics/660862/higher-education-institutions-bytype-india/
[3] Asia Colleges and Universities - https://www.4icu.org/Asia/
[4] EU Colleges and Universities - https://www.4icu.org/Europe/
[5] USA – Large Businesses - https://www.hourly.io/post/number-of-small-business-in-the-us#:~:text=According%20to%20the%20SBA%20Office%20of%20Advocacy%2C%20there%20are%20currently,97.5%20percent%20of%20exporters
[6] India - Large Businesses - https://cse.azimpremjiuniversity.edu.in/wp-content/uploads/2019/12/Mehrotra_Giri_Not_Just_Missing_Middle_Revised_July2020.pdf

[7] Asia - Large Businesses - https://www.statista.com/statistics/1261048/large-global-companies-by-region/#:~:text=In%202020%2C%20there%20were%20estimated,in%20North%20and%20South%20America.
[8] EU and UK - Large Businesses - https://askwonder.com/research/enterprise-businesses-united-kingdom-europe-ex1lolyn3
[9] Small and Mid-sized Enterprises (SMEs)
[10] USA - SMEs - https://ustr.gov/trade-agreements/free-trade-agreements/transatlantic-trade-and-investment-partnership-t-tip/t-tip-12#:~:text=SMEs%20are%20the%20backbone%20of,sector%20jobs%20in%20recent%20decades.
[11] India - SMEs - https://www.statista.com/statistics/718232/india-number-of-msmes-by-type/
[12] Asia - SMEs - https://askwonder.com/research/small-medium-sized-enterprises-smes-asia-where-sme-defined-non-subsidiary-oue4qfo5f#:~:text=The%20short%20answer%20is%20that,including%20Australia%20and%20New%20Zealand).
[13] EU - SMEs - https://www.statista.com/statistics/878412/number-of-smes-in-europe-by-size/
[14] See the TOD™ Project Business Plan for gross sales pro forma and further information.

Table 3

TOD™ Sales Compared to Computer Industry

Annual Computer Sales

Worldwide laptop and desktop computers sales (2020) [1]	302 million units

Computer Gaming Industry

Number of computer gamers worldwide (2020) [2]	1.75 billion people
Worldwide gaming PC shipments (2020) [3]	41.3 million units
Global gaming market value in USD (2020) [4]	314.4 billion USD

Potential Customers Compared to Pro Forma TOD™ System Sales

Total TOD™ Models Sold	Year 2022	Year 2023	Year 2024
Models [14]	10	15,018	167,800
Total (TOD™ Systems Sold)			**182,828**

Notes:

[1] Computer Sales - Sales of laptop and desktop computers exceeded 302 million in 2020, a 13% increase from the year before and the most since 2014, according to market tracker International Data Corp.
https://fortune.com/2021/01/11/covid-computer-sales-lenovo-hp-dell-apple/

[2] Computer Gamers - In 2020, there were an estimated 1.75 billion PC gamers worldwide, up from 1.5 billion PC gaming users in the previous year.
https://www.statista.com/statistics/420621/number-of-pc-gamers/#:~:text=In%202020%2C%20there%20were%20an,titles%20accessible%20for%20gamers%20worldwide.

[3] Worldwide gaming PC shipments
https://www.pcmag.com/news/pc-gaming-market-expected-to-thrive-even-as-pandemic-wanes

[4] The Global Gaming Market - was valued at USD 173.70 billion in 2020, and it is expected to reach a value of USD 314.40 billion by 2026.
https://www.mordorintelligence.com/industry-reports/global-gaming-market

Table 4

Commercially Available TOD™ Models and Pricing

TOD™ Model	Max Neuron Capacity [1] [2]	Number of TC Arrays [3]	Number of TC-Disks	Baseline Price $ Millions [4] [5] [6]
Model 16	16 million	1	16	0.6
Model 48	48 million	3	48	1.8
Model 64	64 million	4	64	2.6
Model 96	96 million	6	96	3.4
Model 192	192 million	12	192	6.6
Model 480	480 million	30	480	Inquire
Model 1024	1024 million	64	1024	Inquire
Model 2048	2048 million	128	2048	Inquire
Model 5120	5120 million	320	5120	Inquire

Notes:
[1] The actual number of neurons present at any given time will vary due to many factors that affect neuron birth, death, and growth rates. BCM cannot, therefore, guarantee the number of neurons in any specific TC Disk. However, every BCM manufactured TC Disk is designed to support one million neurons.
[2] TC Disk neuron population density is established by tissue and other factors. The human brain has 100 billion neurons in a volume of about 1500 cc, or 91.5 cubic inches. Each TC Disk is approximately 2x2x0.5 inches or 2 cubic inches, establishing a maximum capacity of one million neurons per TC Disk.
[3] The Model 16 Tissue Computer planar array has 16 TC Disks in a 4x4 array. The Model 48 cubic array has 48 TC Disks in a 3D structure of a 3 deep 4x4 array. The 3D structure of the cubic array is the basis for all Tissue Computer architectures in the larger TOD™ Models.

Table 5

Available TOD™ Purchase Payment Programs [1]

TOD™ Model	Initial Payment [2]	Intermediate Payment [3]	Final Payment [4]
Model 16	40%	40%	20%
Model 48	60%	20%	20%
Model 64	70%	10%	20%
Model 96	80%	n/a	20%
Model 192	80%	n/a	20%
Model 480	90%	n/a	10%
Model 1024	90%	n/a	10%
Model 2048	90%	n/a	10%
Model 5120	90%	n/a	10%

Notes

[1] BCM welcomes full payment with any purchase order; however, various payment plans are offered, as outlined above. The use of a percentage (%) represents a percentage of the total price of the purchase as defined in the purchase order. Third-party financial service providers may offer various equipment leasing and loan programs for qualified purchasers; contact a BCM sales representative for details.

[2] The first payment is due with or following, the acceptance by BCM of a signed purchase order and purchase agreement. Upon receipt of the first payment, BCM will commit, in writing, to a slot in the manufacturing process for the purchased TOD™ Model(s). As stated in the purchase agreement, there is no guarantee that any planned manufacturing commencement date, slot, or delivery date will be achieved or that changes in such dates will not occur.

[3] For those Models that have a second payment, the payment is due no later than forty-five (45) days before the proposed delivery and installation date. Per the purchase agreement, failure to timely deliver this payment may result in a delay and/or rescheduling of the delivery and install date, and possible financial penalties.

[4] The last payment is due and payable no later than thirty (30) days after the actual date of the Model delivery and installation.

Table 6

TOD™ Manufacturing and Sales Pro Forma

TOD™ Model Number [1]	Number Units Delivered [2]	Gross Sales $ Billions [3]
Year 2022 (4th Quarter)		
Model 16	10	0.006
Totals	10	0.006
Year 2023 (All Quarters)		
Model 16	12,000	7.2
Model 48	2,400	4.32
Model 64	600	1.56
Model 96	12	0.041
Model 192	6	0.04
Totals	15,018	13.16
Year 2024 (All Quarters)		
Model 16	120,000	72
Model 48	40,000	72
Model 64	6,000	15.6
Model 96	1,200	4.1
Model 192	600	3.96
Totals	167,800	167.66

Notes:
[1] This Pro Forma excludes production and sales of all large TOD™ Models (480 through 5120). The number of these units sold, the actual purchase prices, and other factors are highly dependent upon each of the large unit customers and are therefore difficult to forecast and have been excluded from this Table.

[2] This Model quantity production and delivery Plan is preliminary and subject to the receipt of approved and funded purchase orders. The mix of actually produced orders and sales may vary from this Pro Forma and such variation will impact production schedules and Pro Forma revenues. TOD™ Model sales purchase orders may exceed actual available manufacturing capacity, which will result in sliding out of planned delivery dates and impact Pro Forma revenues.
[3] Revenues are based upon the listed quantities by TOD™ Model(s) and all purchases are at the baseline prices defined in this Plan. There is no assurance these Pro Forma will be obtained, or if obtained, that any benefits will arise. These results and data are subject to change without notice. Source data for this Pro Forma is BCM management and the BCM Business Plan, TOD™ Project, February 2022.

Table 7

Pro Forma Annual BCM Revenues

Annual Total Revenues from TOD™ System Sales Only [1]

Year	2022	2023	2024	2025	2026
Units Sold [2]	10	15,018	167,800	189,400	209,250
BCM Revenues ($ billions USD)					
Totals	-	13.16	168	197	212

Notes:
[1] This Pro Forma is limited to only TOD™ systems and services. There is no assurance these Pro Forma will be obtained, or if obtained, that any benefits will arise. These results and data are subject to change without notice. Source data for this Pro Forma is BCM management and the BCM Business Plan, TOD™ Project, February 2022.
[2] The total global number of TOD™ systems sold during the calendar year.

Table 8

Pro Forma BCM Five-Year Earnings and Valuation

Annual Total Earnings and Valuation from TOD™ System Sales Only [1]

Year	2022	2023	2024	2025	2026
Annual Revenues ($ billions USD) [2]	-	13.6	168	197	212
Annual Net Earnings [3] ($ billions USD)	-	2.6	33.6	39.4	42.4
BCM Valuation P/E Based [4] ($ billions USD)	-	52.6	672	788	848
BCM Share Valuation [5] ($ USD)	-	105	1,344	1,576	1,696

Notes:
[1] This Pro Forma is limited to only revenues received for TOD™ system sales and services. All other BCM products and services sales and revenues are excluded.
[2] Annual revenues are gross global sales of TOD™ system and services in USD.
[3] Net earnings are projected at 20% of annual gross global revenues. To achieve this level of earnings, BCM has designed an extremely efficient and highly automated TOD™ manufacturing facility. These facilities commence operations in the year 2023 and are expanded in the years 2024 and 2025.
[4] This Pro Forma utilizes a price-earnings ratio (P/E) of 20, and the earnings (E) in this analysis are defined as net, post-tax payments, and global earnings.
[5] BCM share valuation is based upon a total of 500 million shares and options issued and outstanding during the period of the Pro Forma. There is no assurance these Pro Forma will be obtained, or if obtained, that any benefits will arise. These results and data are subject to change without notice. Source data for this Pro Forma is BCM management and the BCM Business Plan, TOD™ Project, February 2022.

>>><<<